Ryan N Hansen
Overview
Explore the profile of Ryan N Hansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
1854
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hernandez I, Gabriel N, Pathak Y, Hansen R, Sullivan S
JAMA Health Forum
. 2025 Feb;
6(2):e250012.
PMID: 40019743
No abstract available.
2.
Gold L, Heagerty P, Hansen R, Friedly J, Johnston S, Deyo R, et al.
Pain
. 2024 Dec;
PMID: 39679717
Given the negative impact of opioid use on population health, prescriptions for alternative pain-relieving medications, including gabapentin, have increased. We wanted to determine whether people who filled gabapentin and opioid...
3.
Gold L, Heagerty P, Hansen R, Friedly J, Deyo R, Curatolo M, et al.
medRxiv
. 2024 Nov;
PMID: 39502660
Background Context: Recent work indicates no increased mortality risk with concurrent gabapentin and opioid use when using an active comparator control design. However, concurrent gabapentin and opioid prescriptions have been...
4.
Cousin E, Sullivan S, Hansen R, Gabriel N, Kirihennedige A, Hernandez I
J Manag Care Spec Pharm
. 2024 Sep;
30(11):1203-1210.
PMID: 39298335
Background: The Centers for Medicare and Medicaid Services (CMS) recently announced the Maximum Fair Price for the first 10 Medicare Part D drugs selected for price negotiation. By February 2025,...
5.
Sun L, Dayer V, Hansen R, Du Y, Williamson T, Kong S, et al.
JACC Adv
. 2024 Aug;
3(7):101027.
PMID: 39130027
Background: Approximately one-half of all heart failure (HF) consists of heart failure with preserved ejection fraction (HFpEF) or heart failure with mid-range ejection fraction (HFmrEF). Although several recent trials have...
6.
Hernandez I, Sullivan S, Hansen R, Fendrick A
J Manag Care Spec Pharm
. 2024 Jul;
30(7):719-727.
PMID: 38950157
Drug shortages threaten patients' access to medications and are associated with adverse health outcomes and increased costs. Drug shortages disproportionately occur among generic drugs of limited profitability, most notably drugs...
7.
Floyd A, Silcox J, Strickler G, Nong T, Blough M, Bolivar D, et al.
Drug Alcohol Depend Rep
. 2024 Jul;
11:100243.
PMID: 38948428
Background: As the US opioid-involved morbidity and mortality increase, uptake and implementation of evidence-based interventions remain key policy responses. Respond to Prevent was a multi-component, randomized trial implemented in four...
8.
Gold L, Heagerty P, Hansen R, Friedly J, Johnston S, Deyo R, et al.
medRxiv
. 2024 May;
PMID: 38746254
Importance: Given the negative impact of opioid use on population health, prescriptions for alternative pain-relieving medications, including gabapentin, have increased. Concurrent gabapentin and opioid prescriptions are commonly reported in retrospective...
9.
Gold L, Hansen R, Mayer-Hamblett N, Nichols D, Gifford A, Kloster M, et al.
J Manag Care Spec Pharm
. 2023 Dec;
30(1):26-33.
PMID: 38153868
Background: Dornase alfa and hypertonic saline are mucoactive therapies that can improve respiratory symptoms in people with cystic fibrosis (CF). A recent randomized control trial showed that participants with well-preserved...
10.
Hernandez I, Gabriel N, Kaltenboeck A, Boccuti C, Hansen R, Sullivan S
JAMA
. 2023 Dec;
330(24):2390-2392.
PMID: 38051277
No abstract available.